3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Burkitt Lymphoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Dendritic Cell Sarcoma, Interdigitating
1
Cardiotoxicity
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Interventions
Razoxane
4
Doxorubicin
4
Dexrazoxane
4
Vincristine
3
Etoposide
3
Radiotherapy
2
Prednisone
2
Methotrexate
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Bleomycin
2
hydrocortisone hemisuccinate
1
Watchful Waiting
1
Trastuzumab
1
Proton Therapy
1
Observation
1
Mercaptopurine
1
Leucovorin
1
Ifosfamide
1
Hydrocortisone
1
Enalapril
1
Cytarabine
1
Cyclophosphamide
1
Cisplatin
1
Carvedilol
1
Asparaginase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Cardiotoxicity
×
hydrocortisone hemisuccinate
×
Clear all
NCT01230983
2013-06-06
T-Cell #4
Children's Oncology Group
Phase 3
Completed
573 enrolled